

## 9. Cost Effectiveness

Tobacco treatment programs are among the most cost effective interventions available. Combining counselling and pharmacotherapy is the most effective intervention and may increase chances of a successful quit attempt five-fold.<sup>19</sup>

## 10. Moving Forward

You can help patients at any stage along the quit process, from those currently unwilling to quit, to those who have recently quit. There are many resources available to learn more about pharmacological options and the general principles of cessation counselling.<sup>19,23</sup>

### References

1. Doll R, Hill AB. Smoking and carcinoma of the lung; preliminary report. *Br Med J* 1950; 2(4682):739-48.
2. Sugiyama D, Nishimura K, Tamaki K, et al. Impact of smoking as a risk factor for developing rheumatoid arthritis: A meta-analysis of observational studies. *Ann Rheum Dis* 2010; 69(1):70-81.
3. Di Giuseppe D, Discacciati A, Orsini N, Wolk A. Cigarette smoking and risk of rheumatoid arthritis: A dose-response meta-analysis. *Arthritis Res Ther* 2014; 16(2):R61.
4. Videm V, Cortes A, Thomas R, Brown MA. Current smoking is associated with incident ankylosing spondylitis - the HUNT population-based norwegian health study. *J Rheumatol* 2014; 41(10):2041-8.
5. Ciurea A, Finckh A. Smoking and spondyloarthritis. *Joint Bone Spine* 2013; 80(3):234-5.
6. Chung HY, Machado P, van der Heijde D, D'Agostino MA, Dougados M. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: Results from the DESIR cohort. *Ann Rheum Dis* 2012; 71(6):809-16.
7. Freemer MM, King TE, Jr, Criswell LA. Association of smoking with dsDNA autoantibody production in systemic lupus erythematosus. *Ann Rheum Dis* 2006; 65(5):581-4.
8. Majka DS, Holers VM. Cigarette smoking and the risk of systemic lupus erythematosus and rheumatoid arthritis. *Ann Rheum Dis* 2006; 65(5):561-3.
9. Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. *J Autoimmun* 2010; 34(3):J314-21.
10. Naldi L, Mercuri SR. Smoking and psoriasis: From epidemiology to pathomechanisms. *J Invest Dermatol* 2009; 129(12):2741-3.
11. Hojgaard P, Grintborg B, Hetland ML, et al. Association between tobacco smoking and response to tumour necrosis factor alpha inhibitor treatment in psoriatic arthritis: Results from the DANBIO registry. *Ann Rheum Dis* 2014. [epub ahead of print].
12. Kaan U, Ferda O. Evaluation of clinical activity and functional impairment in smokers with ankylosing spondylitis. *Rheumatol Int* 2005; 25(5):357-60.
13. Saevardsdottir S, Wedren S, Seddighzadeh M, et al. Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from the epidemiological investigation of rheumatoid arthritis and the swedish rheumatology register cohorts. *Arthritis Rheum* 2011; 63(1):26-36.
14. Saevardsdottir S, Rezaei H, Geborek P, et al. Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: Results from the SWEFOT trial. *Ann Rheum Dis* 2014. [epub ahead of print].
15. Soderlin MK, Petersson IF, Bergman S, Svensson B, BARFOT study group. Smoking at onset of rheumatoid arthritis (RA) and its effect on disease activity and functional status: Experiences from BARFOT, a long-term observational study on early RA. *Scand J Rheumatol* 2011; 40(4):249-55.
16. Saeki Y, Matsui T, Kagawa K, et al. Smoking cessation significantly reduces failure of biologics (bio)-treatment in rheumatoid arthritis (RA): From the "NINJA" registry cohort of japanese patients (ABSTRACT SAT0074). *Ann Rheum Dis* 2014; 73.
17. Borland R, Partos TR, Yong HH, Cummings KM, Hyland A. How much unsuccessful quitting activity is going on among adult smokers? Data from the international tobacco control four country cohort survey. *Addiction* 2012; 107(3):673-82.
18. CAN-ADAPT. Canadian smoking cessation clinical practical guideline. Toronto, Canada: Canadian Action Network for the Advancement, Dissemination and Adoption of Practice-informed Tobacco Treatment, Centre for Addiction and Mental Health. 2011.
19. Treating Tobacco Use and Dependence 2008 Update. U.S. Department of Health and Human Services, Public Health Service Report. 2008.
20. Stead, L.F., Perera, R., Bullen, C., Mant, D. & Lancaster, T. 2008, "Nicotine replacement therapy for smoking cessation", *The Cochrane database of systematic reviews*, vol. (1):CD000146. doi, no. 1, pp. CD000146.
21. Fucito LM, Bars MP, Forray A, et al. Addressing the evidence for FDA nicotine replacement therapy label changes: A policy statement of the association for the treatment of tobacco use and dependence and the society for research on nicotine and tobacco. *Nicotine Tob Res* 2014; 16(7):909-14.
22. U.S. Food and Drug Administration. Nicotine therapy replacement labels may change. FDA Consumer Health Information. 2013.
23. U.S. Department of Health and Human Services. The Health Consequences of Smoking - 50 Years of Progress. A report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health. 2014.

*Adam Ramzy, BHSc*

*UBC MD/PhD Student,*

*Laboratory of Dr. Timothy Kieffer*

*Diabetes Research Group,*

*University of British Columbia*

*Vancouver, British Columbia*

*Milan Khara, MBChB, CCFP, ABAM*

*Smoking Cessation Clinic*

*Vancouver General Hospital*

*Vancouver, British Columbia*

## Fracture Liaison Service: Update

Plans for implementation of Fracture Liaison Services (FLS) are ongoing in several jurisdictions across Canada. To support ongoing implementation of FLS, Osteoporosis Canada has developed Quality Standards for FLS in Canada. The CRA has endorsed these Quality Standards, along with the Canadian Orthopedic Association, the Canadian Orthopedic Nurses Association, and Bone and Joint Canada. The list of endorsing organizations will be updated as additional endorsements are received.

The Quality Standards provide a concise set of statements which describe the most important functions of an FLS and which provide very clear guidance for healthcare professionals and administrators on what a world-class FLS will actually deliver. The Quality Standards will help ensure that any FLS can be set up for success at the time of implementation. These Standards are in compliance with the 2010 Osteoporosis Canada Clinical Guidelines and the International Osteoporosis Foundation Capture the Fracture Best Practice Framework for FLS.

Download the Quality Standards for FLS in Canada from [www.osteoporosis.ca/fls](http://www.osteoporosis.ca/fls).